Our Story
In 2017, Intelligencia AI emerged as the result of passion and persistence of its founders who recognized the necessity to improve the $1.5 trillion global pharmaceutical industry.
Ever-increasing costs, long timelines and shrinking ROI have plagued the industry for many years. Since the beginning, Intelligencia AI has been de-risking and streamlining drug development by applying the latest AI-based innovations and utilizing the billions of medical and scientific data points to improve the predictive power of probability of success—one step closer to bringing lifesaving treatments to patients sooner.
To succeed, the company grew with an interdisciplinary and global team of professionals with broad experience in data science, clinical data, biological and medical research, and business operations.
We’re passionate about enabling biopharmaceutical companies to enhance efficiency – not just from a clinical development and business growth perspective – but to influence the ability to bring novel treatments to patients, faster. This – bringing treatments to patients faster – is what drives us.
Our Mission
Empower life sciences companies to accelerate clinical development and de-risk business decisions with AI-driven solutions.
Our Vision
Our vision is to be a catalyst for change. By pioneering the advancement of AI in drug development, we support bringing groundbreaking therapies to market that will transform lives.
Meet Our Leadership Team
Our global leadership team throughout the U.S. and Europe brings a wide range of skills, talents and experiences in the health, tech and life sciences industries to Intelligencia AI. Get to know them.
Dimitrios Skaltsas
CEO & Co-founder
Modal Title
Dimitrios Skaltsas, MBA
CEO & Co-founder
As the CEO and co-founder of Intelligencia AI, Dimitrios Skaltsas leads the AI-based technology organization’s business and investment growth strategy, while overseeing key functional areas of the multidisciplinary, growing team. In 2021, the company completed its Series A funding and was named one of Forbes’s Top AI Companies to Watch. During this time, Dimitrios played an instrumental role in forging a strategic partnership with ZS, a global professional services company. Before tapping into his entrepreneurial spirit and co-founding Intelligencia AI, Dimitrios spent over a decade in various healthcare and life sciences leadership roles.
He successfully led McKinsey’s New Ventures for big data and AI in the pharmaceutical R&D sector, where he pioneered machine learning-enabled enterprise products in life sciences. Before that, he worked as a management consultant at McKinsey, supporting healthcare and life sciences clients in North America, Europe and the Middle East. He began his career as an attorney before moving into the health tech industry.
In addition to his professional interests, Dimitrios uses his talents and time to give back to the community. Since 2021, he has been an active member of the Hellenic Republic National Commission for Bioethics & Technoethics. He also volunteers with TechnoServe, a nonprofit that works with enterprising people in the developing world to build competitive farms, businesses and industries. In addition, he serves as an executive in residence for digital and AI at Institut Européen d’Administration des Affaires (INSEAD) where he has actively built online education modules on AI. He is also an investor and advisor to early-stage data-driven ventures.
He holds his MBA from INSEAD and a law degree from the University College of London (UCL) and the University of Athens.
In his leisure time, you can find him painting, enjoying the countryside and connecting with people.
Alexandra Ferraro
Head of Marketing
Modal Title
Alexandra Ferraro
Head of Marketing
Alex leads the marketing function at Intelligencia AI where she works on both strategy and campaign execution to elevate the organization’s brand and drive demand for its AI-driven solution to help de-risk drug development.
Prior to this role, she has held various marketing positions in the health tech and pharma space. Most recently, she was the Vertical Marketing Manager for the life sciences and health tech areas for the Healthcare Business of LexisNexis®Risk Solutions, where she was instrumental in launching the company’s next-generation tokenization solution in January 2022.
On a personal note, Alex enjoys the warm weather in sunny South Florida, where she spends quality time with her family, testing out new recipes in the kitchen, traveling both near and far, reading fiction novels at the beach, and indoor cycling.
Antonis Stampoulis
Director of Engineering
Modal Title
Antonis Stampoulis, PhD
Director of Engineering
As a Director of Engineering, Antonis leads the engineering team that builds clinical trial data tooling, including tools for expert curation and automated data-capturing workflows.
Prior to joining Intelligencia AI, Antonis was the director of engineering at Originate NYC, a product design and development studio, working with software teams in various industries including fin-tech, SaaS platforms, and retail. In this capacity, his role included building and tech-leading software products, as well as managing the engineering team. He also spent time as a freelance consultant focusing on programming language design and strategic advice for software start-ups.
Antonis spends his free time enjoying all forms of art, playing the guitar and the oud, reading, and exploring NYC and Athens.
Edoardo Madussi
Head of Business Development
Modal Title
Edoardo Madussi
Head of Business Development
As a Business Development Director, Edo supports clinical development, portfolio management, and business development and licensing teams in the biopharma sector. He focuses on how implementing Intelligencia AI’s artificial intelligence platform enhances decision-making processes in drug development.
His career includes pivotal roles in globally recognized firms, such as the Petrone Group, where he successfully launched the Clinical Trials Business Unit, founding its presence in the U.S. and promoting cross-functional integration across the group’s affiliates worldwide. As the Country Head and Managing Director, he initiated and led business development efforts, securing contracts with international partners in the U.S., Canada, and LATAM. In his previous role as Commercial Director of Business Development at Inceptua, Edoardo transformed the Clinical Trial Supply Services landscape, consistently innovating the space by introducing cutting-edge practices.
Edoardo holds two master’s degrees, one from the Virginia Polytechnic Institute and State University, specializing in international business administration, corporate strategy, and health economics. The second was in Health Management from the University of Lugano, Switzerland (USI), where he focused on health communication systems, epidemiology, and outcome research. His academic journey included research on the positive effects of doctor-patient interactions on health outcomes.
Outside of work, Edoardo founded Mad4cycling, a not-for-profit organization that combines his passion for cycling and networking, uniting people from around the world. Additionally, he is a graduate of the prestigious Swiss Officer’s Academy in Bern, Switzerland.
Elena Valkana
Senior Growth Associate
Modal Title
Elena Valkana
Senior Growth Associate
Elena is a Senior Associate, where she leads investor-related matters and focuses on scaling our internal operations. Previously, she led the health tech portfolio for the Greek office at Endeavor, a global nonprofit organization focusing on high-impact entrepreneurship.
Elena holds a BSc with honors in management from the University of Stirling and an MSc in Entrepreneurship from the University of Amsterdam.
She enjoys any adrenaline-fueled activity – specifically kitesurfing.
Gerry Liaropoulos
Director of Data Science
Modal Title
Gerry Liaropoulos
Director of Data Science
As the Director of Data Science & Bioinformatics, Gerry leads a multidisciplinary team of computational scientists, statisticians and informatics experts. This group develops proprietary machine-learning algorithms and focuses on integrating new information. They also focus on the development of new features that improve the accuracy and usability of the predictions and explore new data-driven solutions to help the pharmaceutical industry make optimal decisions under uncertainty.
Gerry also serves as a machine learning instructor at Constructor Learning in Zurich and as an advisor and instructor at Big Blue Data Academy in Athens.
Gerry finds enjoyment in adventurous outdoor activities, whether it’s kitesurfing or carving down the slopes of the mountains.
Heracles Kasimis
Director of Engineering
Modal Title
Heracles Kasimis
Director of Engineering
Heracles is a Director of Engineering where he oversees the development and maintenance of the company’s external facing and supportive software architecture. This includes the cloud infrastructure, data extraction pipelines, Intelligencia AI’s SaaS platform, analytics/reporting toolchains, and APIs for programmatic data consumption.
Prior to Intelligencia AI, he worked for more than 12 years as a software engineer in the information technology sector, designing, developing, and maintaining numerous web applications and services.
Heracles has a bachelor’s in computer science from the University of Southampton.
Maria Georganaki
Director of Product
Modal Title
Maria Georganaki
Director of Product
Maria is the Director of Product at Intelligencia AI where she leads multidisciplinary teams and drives product development strategies that align with the company’s vision. She is passionate about leveraging the power of artificial intelligence to deliver cutting-edge solutions that empower drug development stakeholders to make data-driven decisions.
As a molecular cancer biologist with a background in immuno-oncology, she brings strong clinical knowledge coupled with product development to Intelligencia AI’s solutions. During her doctorate and postdoc studies, Maria was an early-stage researcher for the EU-funded Marie Curie Initial Training Network Tumor Infiltrating Myeloid Cell Compartment (TIMCC) and has co-authored multiple publications in leading journals.
Maria holds her doctorate in medical science, a master’s in molecular medicine from Uppsala University and a bachelor’s in biology from the University of Athens.
Nikos Papadopoulos
Director of Finance
Modal Title
Nikos Papadopoulos
Director of Finance
As the Director of Finance and Compliance Officer, Nikos wears two hats in his multi-faceted role. As the Director of Finance, he oversees the business’s financial operations regarding accounting, tax, payroll and budgeting. And in his Compliance Officer function, he guides the company’s code of ethics by working with People Operations.
Concurrently to his role at Intelligencia AI, he has been the CEO and founder of his own accounting and consulting firm in Greece since 2013.
On a personal note, Nikos was a semi-professional basketball player and participated in the Greek National C Division for two seasons. In his free time, he loves traveling, spending time with friends and keeping active with sports.
Panos Karelis
Director of Insights Excellence
Modal Title
Panos Karelis
Director of Insights Excellence
As the Director of Insights Excellence, Panos leads the newly created Center of Insights Excellence at Intelligencia AI, where he’s focused on unlocking value for the company’s partners through best-in-class thought partnerships and bespoke analytics that harness the company’s proprietary data.
He brings more than a decade of experience in the life sciences industry, helping North American and European pharmaceutical and biotech companies develop product, therapeutic area and portfolio strategies. Prior to joining Intelligencia AI, Panos was a Principal with Strategic Decisions Group, a management consulting firm with a special focus on decision-making. Before moving into strategy consulting and the health tech industry, he began his career in the energy sector. He is an engineer by training with a background in economics, finance and decision analysis.
Panos is also a business mentor who coaches technology startups in developing their business plans, and serves the Greek Alumni Association of Stanford University as a board member. In his leisure time, he enjoys reading literature, staying active with sports and spending time with friends.
Phoebe Prosalika
Director of People Operations
Modal Title
Phoebe Prosalika
Director of People Operations
As the Director of People Operations, Phoebe is responsible for overseeing all aspects of talent management, nurturing the organization’s culture, and fostering employee engagement.
Before joining Intelligencia AI, Phoebe served as the Head of the People Operations department at Beat, a ride-hailing app, during a time of rapid growth at the company. She played a pivotal part in the company’s international expansion efforts, operating within a diverse and cross-cultural environment.
Beyond her professional career, Phoebe’s passion for travel has taken her to over 40 countries across 5 continents. Her commitment to making a positive impact extends to her volunteer work with various nonprofit organizations, with a primary focus on supporting refugees. Driven by her desire to help people reach their full potential, she is a certified coach dedicated to people’s personal and professional development.
Meet Our Scientific
and Corporate Advisors
Our world-class scientific and corporate advisors provide us with invaluable guidance: from the science behind our product to pharmaceutical industry knowledge, from artificial intelligence expertise to corporate experience.
Névine Zariffa
Scientific Advisory Board Chair
Modal Title
Névine Zariffa, M. Math
Scientific Advisory Board Chair
Névine Zariffa is the Chair of Intelligencia AI’s Scientific Advisory Board. In this role, she provides strategic guidance on the company’s product development and roadmap while leading and coordinating the activities of the scientific advisory board.
She is a highly accomplished thought leader in the fields of biostatistics and data science with extensive experience across all phases of drug development. Most recently she served as the SVP of Biometrics and Information Sciences at AstraZeneca (AZ).
Over her 25-year pharma career, she held senior roles at GlaxoSmithKline and AZ where she also led the enterprise data & analytics initiative. She has been a key contributor to development strategies for over 200 drug projects across oncology, cardiovascular, metabolic, respiratory, inflammation, and renal diseases. Névine was a reviewer for The Lancet and has over 30 peer-reviewed publications to her name.
She is currently a strategic consultant to several organizations including scientific data consortia such as ctMoniTR. She advised the FDA, Office of the Commissioner, on the application of real-world evidence to COVID-19 and further supported COVID-19 efforts through her work at the Bill and Melinda Gates Foundation. In addition to Intelligencia AI, she currently serves on the Scientific Advisory Board of ANOVA, ZS Associates and Beaconcure. She was a board member of CDISC for six years. In 2021, she published her first novel, Sisters Pieced Together.
She holds her master of math degree in statistics from the University of Waterloo, and her bachelor of science in pure math from McGill University.
Aiman Shalabi
Scientific Advisor
Modal Title
Aiman Shalabi, PharmD, MBA
Scientific Advisor
As a scientific advisor to Intelligencia AI, Aiman helps guide the organization on overall strategy and how the health tech company can help pharmaceutical organizations bring better medicines to patients, faster.
Aiman has 25 years of experience in healthcare innovation. He is currently the managing director and CEO of a healthcare holding/investment company funded by Sheikh Fawaz Alhokair in Saudi Arabia and also serves as an adjunct professor at Georgetown University.
Previously Aiman was the Global VP for Cell and Gene Therapies at GSK, Global VP for Immuno-Oncology with AstraZeneca, VP of Global Medical Affairs at AstraZeneca, and Head of Immuno-Oncology at MedImmune. Aiman also served as the Chief Medical Officer at the Cancer Research Institute and has consulted for cancer collaborative research groups (US, EU, Asia) while also holding teaching roles in academic centers including Harvard Business School and Georgetown University.
In the pharmaceutical industry, he has led global teams that delivered four new cancer medicines and gained approval from global regulators including the FDA, EMEA, PMDA, and sFDA generating over $2B in annual revenues.
Aiman started his career at the National Cancer Institute (NIH), where he managed 26 cancer medicines, and was awarded by U.S. President Bill Clinton for providing early access to medicines for leukemia (Gleevec) and breast cancer (Herceptin).
Aiman holds five university degrees including two post-graduate degrees (PharmD, MBA).
Vassilis Gorgoulis
Scientific Advisor
Modal Title
Vassilis Gorgoulis, MD, PhD
Scientific Advisor
In his advisor role for Intelligencia AI, Professor Gorgoulis is involved with the supervision of projects associated with drug repurposing and machine learning to evaluate molecular targets and mechanisms in oncology. He and his group have teamed up with Intelligencia AI’s bioinformatics and data science team to provide solutions that involve AI techniques in order to decipher key mechanisms in cancer biology with the main goal of discovering novel therapeutics.
Prof. Gorgoulis is a molecular pathologist who is internationally recognized in the fields of genomic instability in cancer, cellular senescence and machine learning algorithms for predicting drug response in cancer.
Currently, he is a professor and the Director of the Department of Histology – Embryology (DHE), Medical School, National and Kapodistrian University of Athens, Greece. He is also a professor and Chair of Clinical and Molecular Pathology, at Medical School, University of Dundee, UK.
Additionally, he serves as an adjunct professor in the Biomedical Research Foundation, Academy of Athens, Greece; is an honorary professor, at the Institute of Cancer Sciences, University of Manchester, UK; visiting professor, at the Faculty of Health and Medical Sciences, University of Surrey, UK; and an elected member in the European Molecular Biology Organization (EMBO).
Prof. Gorgoulis has 337 publications in international peer-reviewed journals, is listed in SCI, and has more than 30,500 citations. He has been actively involved with more than 200 speaking engagements at various international conferences, seminars, etc., and has contributed 14 chapters to international textbooks.
Prof. Gorgoulis graduated in 1988 (Summa Cum Laude) and received his PhD in 1994 (Summa Cum Laude) from the Faculty of Medicine, National Kapodistrian University of Athens. He received his Medical Specialty in Pathology (Summa Cum Laude) in 1996.
Aristotelis Tsirigos
Scientific Advisor
Modal Title
Aristotelis Tsirigos, PhD
Scientific Advisor
As a scientific advisor, Dr. Tsirigos has played a pivotal role in Intelligencia AI’s development of a cutting-edge machine-learning model designed to forecast the technical and regulatory success of clinical trials. He continues to provide guidance and expertise to the growing company, leveraging his extensive knowledge and experience in machine learning and bioinformatics.
Dr. Tsirigos is a professor of medicine and pathology at the NYU School of Medicine where he also serves as the co-director of precision medicine and director of applied bioinformatics. He leads a team of 25+ computational biologists and data scientists and his research focus is primarily on cancer epigenetics, chromatin organization, and AI-based diagnostics in cancer and other diseases.
Dr. Tsirigos has more than 20 years of experience in genomics and machine learning at NYU and IBM Research. He has co-authored more than 150 studies in peer-reviewed journals, including high-impact studies in cancer epigenetics, chromatin organization, high-throughput single-cell transcriptomic analyses, and precision diagnostics using deep learning.
He received his doctorate in computer science from the Courant Institute of New York University and his bachelor’s from the National Technical University of Athens, Greece.
Pete Georgiadis
Corporate Advisor
Modal Title
Pete Georgiadis, MBA
Corporate Advisor
Pete Georgiadis serves as a corporate advisor to Intelligencia AI.
He is a serial entrepreneur, experienced operator and the founder and CEO of Synetro Group, a Chicago-based private investment and strategic advisory firm. Since founding Synetro in 2000, he has led the firm’s investment in over 50 companies and has personally helped build more than a dozen software, business services and manufacturing companies, including Insurance Noodle Inc., Knowledge Advisors Inc., Kalamazoo Outdoor Gourmet, CrossCheck Compliance, Corporate Synergies Group and dScout, Inc. He currently serves as the Chairman and CEO of Pleina Group, and sits on the boards of CrossCheck Compliance and dScout, Inc.
Prior to founding Synetro, Pete was the COO of Lante Corporation, a technology consulting firm. He led the strategic repositioning and operating transformation of Lante and prepared it for a successful IPO. Before Lante, he was with McKinsey and Company, where he was a leader in the firm’s marketing and sales & channel management practices. He started his career at Hewlett-Packard Co., in marketing and general management roles in the UK and Switzerland.
Pete holds an MBA from Harvard Business School, a master’s of computer science from London’s Imperial College and a bachelor’s of science in electronic engineering from the University of Sussex. He is a committed supporter of a number of educational and social service organizations in the U.S. and Europe.
Simo Kamppari
Corporate Advisor
Modal Title
Simo Kamppari, MBA
Corporate Advisor
As a corporate advisor, Simo supports Intelligencia AI’s continued business growth, as the company continues to evolve and navigates various business dynamics.
As an engineer, Simo has a passion for building products and businesses. Since 2010, he has been actively investing in and supporting the growth of a range of companies in the technology and business services industries. Serving in roles ranging from investor to board member, to an active operating team member, Simo is passionate about working with teams committed to building exceptional solutions and great companies.
Previously, Simo worked for five years as a management consultant at McKinsey where he served a broad set of financial services clients. Before that, he served as a group manager, specializing in the development of enterprise software at Oracle.
Simo holds bachelor’s and master’s degrees in electrical engineering and computer science from Massachusetts Institute of Technology, and an MBA from Harvard Business School. He is a technology enthusiast, skier, and a married father of two living near Philadelphia.
Andreas Beroutsos
Corporate Advisor
Modal Title
Andreas Beroutsos
Corporate Advisor
In his corporate advisory role with Intelligencia AI, Andreas is focused on strategy, finance and talent growth.
As a seasoned private equity investor, he has held leadership roles in various global organizations. Over the past 16 years, he has served as the Senior Investment Executive at BW Group. Prior to this, he served as the Executive Vice President and Global Head of Private Equity and Infrastructure at Caisse de dépôt et placement du Québec (CDPQ), the leading Canadian institutional investor. He was a Senior Partner/Head of Illiquid Investments at Eton Park Capital Management.
Before his investing career, Andreas was a Senior Partner at McKinsey & Company, where he led the global private equity practice, North American financial services and global recruiting. He also served on the committee that elects the firm’s senior partners.
He resides in NY, is active globally, and has served on numerous corporate and not-for-profit boards in education and the arts. He has earned undergraduate and graduate degrees from Harvard University and Harvard Business School.
Violetta Kalathaki
Corporate Advisor
Modal Title
Violetta Kalathaki
Corporate Advisor
As a corporate advisor, Violetta focuses on providing strategic guidance to product development and marketing functions at Intelligencia AI. Before moving into an advisory role, Violetta served as the Chief Product Officer at the company for three years building the product development organization and overseeing product strategy and development.
Violetta brings a breadth of experience, including seven years at Google where she played a pivotal role in developing products such as Adsense Native Ads and spearheading a high-touch growth marketing team for Adwords. Her extensive experience also encompasses valuable consulting insights gained during her tenure at McKinsey, along with a solid foundation in the startup ecosystem.
Violetta holds a master’s degree in economics and management from the London School of Economics and Political Science, and a bachelor’s degree in electrical and computer engineering from The National Technical University of Athens.
Our Core Values
Our values permeate all that we do as a business and as individuals and put us on a path for even greater success as individuals, as a business and for our customers.
We Raise the Bar
We raise the bar in everything we do: excellence is not a destination for us, but a continuous journey. We strive for excellence in all we create, build and deliver, committed to taking initiative, and solving problems with a hands-on approach. We embrace challenges as opportunities to learn and grow, and we constantly seek new and innovative ways to improve our work and create value for our customers.
We Build Together
We believe that teaming up with our colleagues, partners, customers and our stakeholders takes us places we can’t go alone. By working collaboratively we can achieve greater results than we could individually.
We Are Humble
We approach our work and interactions with modesty, respect and an open mindset. We embrace humility acknowledging that we are on a learning journey, part of a larger ecosystem and constantly striving to grow.
We Care
We bring a deep sense of compassion and concern for the well-being of our customers, colleagues, partners and the broader community. As a team, we recognize that our people are our greatest asset, and we are deeply committed to fostering an environment that promotes growth, joy and well-being.
